These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25820765)

  • 1. A cure for the high cost of hepatitis C virus treatment.
    Etzion O; Ghany MG
    Ann Intern Med; 2015 May; 162(9):660-1. PubMed ID: 25820765
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is more expensive always better?].
    Drenth JP
    Ned Tijdschr Geneeskd; 2014; 159():A8556. PubMed ID: 25534272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 4. Sovaldi ushers in wave of costly hepatitis C drugs.
    Manag Care; 2014 Jan; 23(1):51. PubMed ID: 24765752
    [No Abstract]   [Full Text] [Related]  

  • 5. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
    Canary LA; Klevens RM; Holmberg SD
    Ann Intern Med; 2015 Aug; 163(3):226-8. PubMed ID: 26121095
    [No Abstract]   [Full Text] [Related]  

  • 6. Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.
    Liao JM; Fischer MA
    N Engl J Med; 2015 Sep; 373(13):1279-81. PubMed ID: 26398092
    [No Abstract]   [Full Text] [Related]  

  • 7. New expensive treatments for hepatitis C infection.
    Brennan T; Shrank W
    JAMA; 2014 Aug; 312(6):593-4. PubMed ID: 25038617
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of new drugs for chronic hepatitis C: the importance of updating utility values.
    Cortesi PA; Scalone L; Mantovani LG
    Hepatology; 2015 Mar; 61(3):1096-7. PubMed ID: 25043465
    [No Abstract]   [Full Text] [Related]  

  • 9. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
    Einecke D
    MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
    [No Abstract]   [Full Text] [Related]  

  • 10. Commentary on "no to greed".
    Hunt DP
    South Med J; 2015 Jan; 108(1):65-6. PubMed ID: 25580762
    [No Abstract]   [Full Text] [Related]  

  • 11. The high price of the new hepatitis C virus drugs.
    Steinbrook R; Redberg RF
    JAMA Intern Med; 2014 Jul; 174(7):1172. PubMed ID: 24798183
    [No Abstract]   [Full Text] [Related]  

  • 12. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals.
    Modi R; Saab S
    J Infect Dis; 2015 Aug; 212(3):343-4. PubMed ID: 25583165
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply: To PMID 24691835.
    Petta S; Cabibbo G; Cammà C
    Hepatology; 2015 Mar; 61(3):1097. PubMed ID: 25043351
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.
    Mishra P; Florian J; Qi K; Zeng W; Naeger LK; Donaldson E; Connelly S; O'Rear J; Price D; Murray J; Birnkrant D
    Gastroenterology; 2014 Dec; 147(6):1196-200. PubMed ID: 25449024
    [No Abstract]   [Full Text] [Related]  

  • 16. Building bridges and providing transparency to the hepatitis C virus drug approval process.
    Ghany MG; Liang TJ
    Gastroenterology; 2014 Dec; 147(6):1201-3. PubMed ID: 25449025
    [No Abstract]   [Full Text] [Related]  

  • 17. Sofosbuvir-based antiviral therapy for treatment naïve hepatitis C genotypes 1, 2, and 3.
    Sharma P
    Gastroenterology; 2013 Jul; 145(1):245-247. PubMed ID: 23721818
    [No Abstract]   [Full Text] [Related]  

  • 18. Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals.
    Enomoto M; Tateishi C; Tsuruta D; Tamori A; Kawada N
    Ann Intern Med; 2018 May; 168(9):678-680. PubMed ID: 29335738
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C genotype 3: a tough match for interferon-free regimens.
    Aghemo A; Colombo M
    Gastroenterology; 2014 Apr; 146(4):1125-7. PubMed ID: 24566101
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3.
    Bari K; Sharma P
    Gastroenterology; 2014 Aug; 147(2):534-6. PubMed ID: 24953626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.